𝔖 Bobbio Scriptorium

✦ LIBER ✦

Retreatment with bevacizumab in patients with recurrent ovarian cancer does not increase morbidity and has a favorable disease response

✍ Scribed by R. Laskey; S. Richard; A. Smith; J. Lesnock; K. Zorn; P. Sukumvanich; J. Kelley; A. Olawaiye; T. Krivak

Book ID: 113963722
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 55 KB
Volume: 125
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2011.12.167

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Final analysis of overall survival in OC

Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer

✍ Aghajanian, C.; Goff, B.A.; Nycum, L.R.; Wang, Y.; Husain, A.; Blank, S.V. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 116 KB

Late-Breaking Abstract 5: Results from a

Late-Breaking Abstract 5: Results from a 2nd interim OS analysis in OCEANS: A randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)

✍ C. Aghajanian; S. Blank; B. Goff; P. Judson; L. Nycum; M. Sovak; J. Yi; A. Husai 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB